ARTV Stock Forecast & Price Target

Artiva Biotherapeutics is attractive because AlloNK is generating differentiated clinical efficacy across autoimmune disease, with 77% of 21 refractory RA patients achieving ACR50/mACR50 at 6 months and no relapses reported to date, while Sjögren’s data in 11 patients showed ClinESSDAI, ESSPRI, and salivary flow improvements that compare favorably with peers. The company’s safety profile also strengthens the thesis, as across 73 patients there have been no ICANS, CRS, or GvHD reported to date, supporting a potentially more scalable outpatient model than CAR T or TCE approaches. Financially, the balance sheet is reinforced by a pro-forma cash position of $387M and estimated YE:26 cash of $296M, giving it runway well into 2028 and flexibility to advance the pivotal RA program.

Artiva Biotherapeutics is a high-risk early-stage cell therapy company whose lead asset, AlloNK, may fail to deliver durable clinical remissions or be poorly tolerated, which would erode confidence in the platform and reduce the probability of success to 5%. Its pipeline is still in Phase II or earlier, so there is no assurance that it can produce successful clinical candidates, especially against a crowded field of active cell therapy competitors and emerging bispecific therapeutics. The company also faces meaningful regulatory and financing risk because no NK cell therapies have been approved by the FDA or EMA to date, and it will likely need additional capital to advance trials and commercialize any product on favorable terms.